ArticleLipids in health and disease2026
TyHGB as a predictive marker for preeclampsia: association with increased risk in pregnant women with normal glucose tolerance.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin resistance (IR) is considered a crucial pathophysiological driver of preeclampsia. The triglyceride high-density cholesterol-glucose body index (TyHGB) represents a simple and reliable alternative indicator of IR. This study aimed to test the potential link between TyHGB and the risk of preeclampsia.
methodsThe study enrolled 23,219 singleton pregnant women. TyHGB levels were taken into account to stratify participants into quartiles. Multivariable regression and subgroup analyses focused on examining the independent association between TyHGB and preeclampsia. Model discrimination was evaluated using receiver operating characteristic (ROC) curves, model calibration was assessed via calibration curves, and clinical utility was determined by decision curve analysis (DCA).
resultsThe risk of preeclampsia increased gradually with elevated TyHGB levels. According to logistic regression analysis, in the unadjusted model, each 1-unit increase in TyHGB indicated a 1.61-fold higher risk of preeclampsia, with significant differences across all quartiles. This trend persisted in the third and fourth quartiles after adjusting for all confounders (both P < 0.001). Relative to the lowest quartile, the highest TyHGB quartile exhibited the highest risk of preeclampsia (relative risk [RR]: 3.27; 95% confidence interval [CI]: 2.15–4.97). Subgroup analyses indicated that these associations remained largely unchanged regardless of age and parity. The predictive model yielded an area under the curve (AUC) of 0.682 (95% CI: 0.676–0.688), with a sensitivity of 73.85% and a specificity of 53.82%. The calibration curve demonstrated satisfactory calibration (mean absolute error = 0.002). DCA further confirmed the clinically meaningful utility of the model. AUC comparisons showed that TyHGB outperformed other metabolic indices: the triglyceride-glucose (TyG) index, triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, and fasting glucose.
conclusionsTyHGB was strongly and positively associated with preeclampsia, and such association remained consistent after adjustment for multiple confounding factors. These observations revealed that elevated TyHGB indicated a higher risk of preeclampsia. This study contributed to a practical supplementary tool for preeclampsia screening, which may facilitate better maternal and fetal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.